Stryker Corp (SYK) KPIs and segments
Close on Nov 18, 2026Market cap $121.12BP/E 33.9Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Stryker · năm tài chính kết thúc December 31 (Calendar fiscal year; FY2025 ended December 31, 2025; latest quarter FY2026Q3 ended September 30, 2026)
Nhìn nhanh KPI của Stryker: 44 chỉ số vận hành, trong đó có Consolidated Organic Net Sales Growth YoY, MedSurg & Neurotechnology và Orthopaedics — Organic Net Sales Growth YoY, lấy từ 211 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MedSurg and Neurotechnology:($M)7 | 3,664 | 3,625 | 3,207 | 5,931 | 3,355 | 3,305 | 3,056 | 3,882 | 3,324 | 3,215 | 3,097 | 3,754 | |
United States($M) | 2,494 | 3,577 | 2,983 | 2,978 | 2,417 | 3,044 | 2,585 | 2,495 | 2,394 | 2,896 | |||
Medical($M) | 1,081 | 1,122 | 902 | 1,284 | 985 | 990 | 945 | 1,142 | 938 | 908 | 864 | 1,042 | |
Endoscopy($M) | 1,021 | 1,004 | 868 | 1,145 | 896 | 899 | 867 | 1,006 | 837 | 768 | 778 | 902 | |
Instruments($M) | 996 | 1,003 | 920 | 478 | 949 | 918 | 838 | 790 | 679 | 698 | 667 | 726 | |
International($M) | 713 | 985 | 820 | 793 | 639 | 838 | 739 | 720 | 703 | 858 | |||
Neuro Cranial($M) | 669 | 637 | 616 | 563 | 603 | 541 | 514 | 478 | 764 | ||||
Neurovascular($M) | 566 | 496 | 517 | 539 | 525 | 498 | 406 | 341 | 329 | 327 | 310 | 320 | |
Orthopaedics($M)8 | 2,856 | 2,964 | 2,813 | 1,240 | 2,702 | 2,717 | 2,810 | 2,554 | 2,170 | 2,207 | 2,146 | 2,061 | |
United States($M) | 1,982 | 1,864 | 1,588 | 1,576 | 2,023 | 1,829 | 1,524 | 1,552 | 1,520 | 1,460 | |||
Trauma and Extremities($M) | 1,010 | 1,072 | 1,035 | 1,086 | 960 | 957 | 945 | 996 | 849 | 832 | 830 | 860 | |
International($M) | 831 | 745 | 666 | 675 | 787 | 725 | 646 | 655 | 626 | 601 | |||
Ortho Tech($M) | 754 | 717 | 646 | 651 | 649 | 617 | |||||||
Knees($M) | 635 | 693 | 670 | 749 | 628 | 640 | 639 | 687 | 570 | 602 | 588 | 630 | |
Hips($M) | 453 | 479 | 460 | 499 | 457 | 466 | 443 | 463 | 420 | 428 | 393 | 414 | |
Other($M) | 267 | 203 | 183 | 162 | 222 | 159 | 167 | 164 | 315 | ||||
Spinal Implants($M) | 4 | 3 | 2 | 8 | 6 | 5 | 166 | 186 | 172 | 178 | 171 | 318 | |
Neuro Cranial Instruments($M) | 670 | 681 | 606 | 637 | 616 | 563 | |||||||
Orthopaedic Instruments($M) | 535 | 523 | 489 | 492 | 501 | 484 | |||||||
Other Orthopedics($M) | 219 | 194 | 157 | 159 | 148 | 133 | |||||||
Enabling Technologies($M) | 28 | 28 | 26 | 45 | 34 | 29 | |||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2025)3 | |||||||||||||
United States($M) | 4,950 | 4,959 | 4,476 | 5,441 | 4,571 | 4,554 | 4,440 | 4,873 | 4,109 | 4,047 | 3,914 | 4,356 | |
International($M) | 1,570 | 1,630 | 1,544 | 1,730 | 1,486 | 1,468 | 1,426 | 1,563 | 1,385 | 1,375 | 1,329 | 1,459 | |
MedSurg and Neurotechnology:($M) | 1,052 | 1,019 | 700 | 2,194 | 874 | 846 | 757 | 1,288 | 966 | 903 | 847 | 1,204 | |
Orthopaedics($M) | 891 | 1,008 | 846 | 190 | 876 | 900 | 854 | 794 | 643 | 676 | 605 | 698 | |
MedSurg and Neurotechnology:($M) | 2,297 | 2,282 | 1,916 | 3,804 | 2,061 | 2,041 | 1,881 | 2,400 | 2,011 | 1,928 | 1,859 | ||
Orthopaedics($M) | 2,038 | 2,142 | 1,990 | 995 | 1,933 | 1,950 | 2,035 | 1,882 | 1,609 | 1,631 | 1,555 | ||
MedSurg and Neurotechnology:($M) | 27,647 | 27,280 | 26,909 | 26,912 | 23,115 | 20,804 | |||||||
Orthopaedics($M) | 18,641 | 18,192 | 17,865 | 17,878 | 18,507 | 18,313 | |||||||
Consolidated Organic Net Sales Growth YoY (%)(%)5 | 7.7% | 9.0% | 2.4% | 11.0% | 9.5% | 10.2% | 10.1% | 10.2% | 11.5% | 9.0% | 10.0% | 11.4% | |
Consolidated Unit Volume & Product Mix Growth YoY (%)(%) | 7.6% | 9.0% | 2.1% | 9.1% | 9.7% | 10.3% | 7.9% | 9.3% | |||||
Consolidated Constant Currency Net Sales Growth YoY (%)(%)4 | 7.7% | 9.0% | 1.0% | 10.4% | 9.6% | 10.3% | 12.8% | 11.2% | 12.0% | 9.4% | 10.2% | 11.5% | |
Consolidated U.S. Constant Currency Sales Growth YoY (%)(%) | 8.3% | 8.9% | 0.8% | 11.7% | 11.4% | 12.5% | 13.4% | 11.8% | 11.7% | 9.1% | 11.4% | 12.8% | |
Consolidated International Constant Currency Sales Growth YoY (%)(%) | 6.0% | 9.2% | 1.5% | 6.3% | 4.3% | 3.9% | 10.8% | 9.2% | 13.0% | 10.5% | 6.8% | 7.8% | |
Consolidated U.S. Reported Sales Growth YoY (%)(%) | 8.3% | 8.9% | 0.8% | 11.7% | 11.4% | 12.5% | 13.4% | 11.8% | 11.7% | 9.1% | 11.4% | 12.8% | |
Consolidated International Reported Sales Growth YoY (%)(%) | 5.7% | 11.0% | 8.3% | 10.6% | 6.9% | 6.8% | 7.3% | 7.2% | 12.5% | 7.0% | 4.9% | 8.9% | |
Consolidated Acquisitions & Divestitures Net Impact YoY (%)(%) | 0.0% | 0.0% | -1.4% | -0.6% | 0.1% | 0.1% | 2.7% | 1.0% | 0.5% | 0.4% | 0.2% | 0.1% | |
Consolidated Foreign Currency Exchange Impact YoY (%)(%) | 0.0% | 0.4% | 1.6% | 1.0% | 0.7% | 0.8% | -0.9% | -0.5% | -0.1% | -0.9% | -0.5% | 0.3% | |
Consolidated Reported Net Sales Growth YoY (%)(%) | 7.7% | 9.4% | 2.6% | 11.4% | 10.3% | 11.1% | 11.9% | 10.7% | 11.9% | 8.5% | 9.7% | 11.8% | |
MedSurg & Neurotechnology — Organic Net Sales Growth YoY (%)(%)6 | 9.1% | 9.2% | 0.9% | 12.6% | 8.4% | 11.0% | 10.7% | 10.1% | 12.7% | 9.7% | 11.6% | 11.8% | |
MedSurg & Neurotechnology — Unit Volume & Product Mix Growth YoY (%)(%) | 8.9% | 9.1% | 0.3% | 7.6% | 10.2% | 9.5% | 11.0% | 7.6% | 10.2% | ||||
MedSurg & Neurotechnology — Selling Price Growth Impact YoY (%)(%) | 0.2% | 0.1% | 0.6% | 0.8% | 0.8% | 1.2% | 1.7% | 2.1% | 1.4% | ||||
MedSurg & Neurotechnology — Constant Currency Growth YoY (%)(%) | 9.2% | 9.2% | 3.6% | 16.6% | 13.9% | 16.7% | 14.2% | 11.1% | 12.9% | 9.8% | 12.0% | 12.0% | |
MedSurg & Neurotechnology — Acquisitions / Divestitures Impact YoY (%)(%) | 0.1% | 0.0% | 2.7% | 4.0% | 5.5% | 5.7% | 3.5% | 1.0% | 0.2% | 0.1% | 0.4% | 0.2% | |
MedSurg & Neurotechnology — Foreign Currency Impact YoY (%)(%) | 0.0% | 0.5% | 1.4% | 0.9% | 0.5% | 0.6% | -0.8% | -0.5% | -0.1% | -0.8% | -0.5% | 0.3% | |
MedSurg & Neurotechnology — Reported Growth YoY (%)(%) | 9.2% | 9.7% | 5.0% | 17.5% | 14.4% | 17.3% | 13.4% | 10.6% | 12.8% | 9.0% | 11.5% | 12.3% | |
Orthopaedics — Organic Net Sales Growth YoY (%)(%)5 | 5.9% | 8.6% | 4.1% | 8.4% | 11.4% | 9.0% | 9.3% | 10.2% | 9.7% | 8.0% | 8.0% | 10.7% | |
Orthopaedics — Unit Volume & Product Mix Growth YoY (%)(%) | 5.9% | 8.6% | 4.1% | 11.7% | 9.0% | 9.3% | 9.3% | 8.4% | 8.2% | ||||
Orthopaedics — Constant Currency Growth YoY (%)(%) | 5.9% | 8.7% | -1.8% | 0.9% | 3.1% | 1.1% | 10.7% | 11.3% | 10.8% | 8.9% | 8.0% | 10.7% | |
Orthopaedics — Acquisitions / Divestitures Impact YoY (%)(%) | 0.0% | 0.1% | -5.9% | -7.5% | -8.3% | -7.9% | 1.4% | 1.1% | 1.1% | 0.9% | 0.0% | 0.0% | |
Orthopaedics — Foreign Currency Impact YoY (%)(%) | -0.2% | 0.4% | 1.9% | 1.3% | 0.8% | 0.9% | -1.0% | -0.5% | -0.1% | -1.0% | -0.5% | 0.3% | |
Orthopaedics — Reported Growth YoY (%)(%) | 5.7% | 9.1% | 0.1% | 2.2% | 3.9% | 2.0% | 9.7% | 10.8% | 10.7% | 7.9% | 7.5% | 11.0% | |
Adjusted Non-GAAP Operating Margin (%)(%)13 | 26.2% | 27.4% | 21.1% | 30.2% | 25.6% | 25.7% | 22.9% | 29.2% | 24.7% | 24.6% | 21.9% | 27.2% | |
Adjusted Non-GAAP Gross Margin (%)(%) | 65.4% | 66.0% | 63.6% | 65.2% | 65.0% | 65.4% | 65.5% | 65.3% | 64.5% | 64.2% | 63.6% | 63.9% | |
Adjusted Non-GAAP Net Margin (%)(%) | 20.8% | 21.6% | 16.7% | 24.1% | 20.4% | 20.1% | 18.7% | 24.0% | 20.1% | 20.0% | 18.3% | 22.8% | |
Adjusted R&D Expense (% of Net Sales)(%) | 6.4% | 6.4% | 6.7% | 5.3% | 6.6% | 6.6% | 6.7% | 5.3% | 6.6% | 6.5% | 6.8% | 5.6% | |
Adjusted SG&A Expense (% of Net Sales)(%) | 32.8% | 32.2% | 35.8% | 29.7% | 32.8% | 33.1% | 35.9% | 30.8% | 33.2% | 33.1% | 35.0% | 31.0% | |
Adjusted Effective Income Tax Rate (%)(%) | 16.0% | 16.5% | 14.5% | 16.1% | 14.0% | 15.9% | 13.7% | 15.4% | 15.8% | 15.2% | 12.3% | 14.6% | |
MedSurg & Neurotechnology Segment Operating Margin (%)(%) | 28.7% | 28.1% | 21.8% | 29.0% | 28.3% | 27.6% | 28.7% | 27.6% | 26.8% | ||||
Orthopaedics Segment Operating Margin (%)(%) | 31.2% | 34.0% | 30.1% | 28.8% | 30.1% | 27.2% | 28.3% | 29.3% | 27.0% | ||||
Consolidated Gross Margin Bridge — Volume & Product Mix Impact (bps)(bps) | 60 | 70 | 10 | 70 | 70 | 80 | 60 | 50 | 60 | ||||
Consolidated Gross Margin Bridge — Manufacturing, Cost & Tariffs Impact (bps)(bps) | -20 | -30 | -200 | -30 | 40 | 70 | -90 | -80 | -40 | ||||
MedSurg Segment Margin Bridge — Volume & Mix Impact (bps)(bps) | 70 | 60 | 20 | 90 | 100 | 80 | 340 | 250 | 370 | ||||
MedSurg Segment Margin Bridge — Manufacturing & Cost Impact (bps)(bps) | 50 | 60 | -220 | 110 | 130 | 120 | -310 | -90 | 190 | ||||
Orthopaedics Segment Margin Bridge — Volume & Mix Impact (bps)(bps) | 40 | 50 | -10 | 20 | 10 | 80 | 530 | 740 | 160 | ||||
Orthopaedics Segment Margin Bridge — Manufacturing & Cost Impact (bps)(bps) | -70 | -20 | -190 | -190 | -50 | 40 | 180 | -320 | -50 | ||||
Adjusted Non-GAAP Diluted Net Earnings per Share ($)($)8 | 3.52 | 3.69 | 2.60 | 4.47 | 3.19 | 3.13 | 2.84 | 4.01 | 2.87 | 2.81 | 2.50 | 3.46 | |
Full-Year Guidance Issued in Quarter — Organic Net Sales Growth Low End (%)(%)3 | 6.5% | 8.3% | 8.0% | 8.0% | 8.0% | 9.5% | 9.0% | 8.5% | 7.5% | ||||
Full-Year Guidance — Organic Net Sales Growth High End (%)(%) | 7.0% | 9.3% | 9.5% | 9.5% | 9.0% | 10.0% | 10.0% | 9.5% | 9.0% | ||||
Full-Year Guidance — Adjusted Diluted EPS Low End ($)($) | 14.80 | 14.95 | 14.90 | 14.90 | 13.50 | 13.40 | 13.45 | 12 | 11.90 | 11.85 | 11.70 | ||
Full-Year Guidance — Adjusted Diluted EPS High End ($)($) | 14.90 | 15.10 | 15.10 | 15.10 | 13.60 | 13.60 | 13.70 | 12.10 | 12.10 | 12.05 | 12 | ||
MedSurg & Neurotechnology Segment — Worldwide Net Sales ($M)($M)4 | 3,664 | 3,625 | 3,207 | 3,976 | 3,355 | 3,305 | 3,056 | 4,178 | 3,324 | 3,215 | 3,097 | 3,427 | |
MedSurg & Neurotechnology — Worldwide Constant Currency Growth YoY (%)(%) | 9.2% | 9.2% | 3.6% | ||||||||||
MedSurg & Neurotechnology — Worldwide Reported Growth YoY (%)(%) | 9.2% | 9.7% | 5.0% | ||||||||||
MedSurg & Neurotechnology — U.S. Net Sales ($M)($M) | 2,904 | 2,854 | 2,494 | 3,122 | 2,650 | 2,626 | 2,417 | 2,680 | 2,267 | 2,156 | 2,072 | 2,363 | |
MedSurg & Neurotechnology — International Net Sales ($M)($M) | 760 | 771 | 713 | 854 | 705 | 679 | 639 | 720 | 639 | 617 | 602 | 702 | |
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — Worldwide Net Sales ($M)($M)6 | 996 | 1,003 | 920 | 1,008 | 949 | 918 | 838 | 679 | 698 | 667 | |||
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — Worldwide Constant Currency Sales Growth YoY (%)(%) | 5.2% | 9.0% | 8.7% | ||||||||||
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — Worldwide Reported Sales Growth YoY (%)(%) | 5.1% | 9.3% | 9.9% | ||||||||||
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — U.S. Net Sales ($M)($M)1 | 835 | 840 | 766 | 848 | 797 | 776 | 702 | 769 | 674 | 643 | 600 | 663 | |
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%) | 4.8% | 8.4% | 9.1% | ||||||||||
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — International Net Sales ($M)($M)2 | 161 | 163 | 154 | 160 | 152 | 142 | 136 | 142 | 128 | 127 | 122 | 138 | |
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — International Constant Currency Sales Growth YoY (%)(%) | 7.1% | 12.3% | 7.0% | ||||||||||
Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — International Reported Sales Growth YoY (%)(%) | 6.5% | 13.9% | 14.0% | ||||||||||
Standalone Sub-Portfolio: Neuro Cranial — Worldwide Net Sales ($M)($M)3 | 670 | 681 | 606 | 669 | 637 | 616 | 563 | 603 | 441 | 416 | 380 | 437 | |
Neuro Cranial (Legacy Standalone through FY2025Q4) — Worldwide CC Growth YoY (%)(%) | 10.2% | 17.0% | 19.2% | 18.5% | 15.8% | 15.0% | 12.2% | 7.5% | 13.8% | ||||
Neuro Cranial (Legacy Standalone through FY2025Q3) — U.S. Net Sales ($M)($M) | 524 | 507 | 465 | 366 | 339 | 309 | |||||||
Neuro Cranial (Legacy Standalone through FY2025Q3) — International Net Sales ($M)($M) | 113 | 109 | 98 | 75 | 77 | 71 | |||||||
Instruments (Legacy Pre-2026 Basis, through FY2025Q4) — Worldwide Net Sales ($M)($M)3 | 925 | 760 | 768 | 730 | 790 | 679 | 698 | 667 | 736 | ||||
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — Worldwide Net Sales ($M)($M)4 | 1,021 | 1,004 | 868 | 1,145 | 896 | 899 | 867 | 1,006 | 837 | 768 | 778 | 892 | |
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — Worldwide Constant Currency Sales Growth YoY (%)(%) | 14.0% | 11.3% | -1.0% | 13.6% | 6.7% | 16.7% | 12.1% | 12.3% | 12.5% | 8.3% | 10.5% | 14.4% | |
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — Worldwide Reported Sales Growth YoY (%)(%) | 13.9% | 11.7% | 0.1% | 13.8% | 7.0% | 17.1% | 11.4% | 11.5% | 12.2% | 7.6% | 10.1% | 14.6% | |
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — U.S. Net Sales ($M)($M)1 | 839 | 819 | 701 | 938 | 743 | 742 | 710 | 844 | 689 | 623 | 636 | 747 | |
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%) | 13.0% | 10.2% | -1.2% | 11.1% | 7.9% | 19.1% | 11.6% | 13.1% | 11.3% | 8.2% | 11.1% | 17.9% | |
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — International Net Sales ($M)($M)2 | 182 | 185 | 167 | 207 | 153 | 157 | 157 | 162 | 148 | 145 | 142 | 155 | |
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — International Constant Currency Sales Growth YoY (%)(%) | 18.5% | 16.5% | 0.0% | 26.3% | 0.8% | 6.4% | 14.6% | 8.2% | 18.1% | 9.0% | 8.1% | 0.6% | |
Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — International Reported Sales Growth YoY (%)(%) | 18.0% | 18.8% | 6.0% | 28.1% | 2.6% | 8.3% | 10.6% | 3.9% | 16.6% | 5.3% | 5.9% | 1.1% | |
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — Worldwide Net Sales ($M)($M)4 | 1,081 | 1,122 | 902 | 1,284 | 985 | 990 | 945 | 1,142 | 938 | 908 | 864 | 1,042 | |
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — Worldwide Constant Currency Sales Growth YoY (%)(%) | 9.8% | 13.0% | -5.6% | 11.3% | 4.7% | 8.6% | 10.1% | 10.1% | 17.7% | 8.4% | 11.1% | 11.2% | |
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — Worldwide Reported Sales Growth YoY (%)(%) | 9.7% | 13.4% | -4.6% | 12.4% | 5.1% | 9.0% | 9.4% | 9.6% | 17.6% | 8.0% | 11.0% | 11.4% | |
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — U.S. Net Sales ($M)($M)1 | 910 | 945 | 747 | 1,042 | 827 | 840 | 802 | 930 | 783 | 763 | 715 | 831 | |
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%) | 10.0% | 12.6% | -6.9% | 12.0% | 5.6% | 10.1% | 12.3% | 12.0% | 18.6% | 11.9% | 16.8% | 12.9% | |
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — International Net Sales ($M)($M)2 | 171 | 177 | 155 | 242 | 158 | 150 | 143 | 212 | 155 | 145 | 149 | 211 | |
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — International Constant Currency Sales Growth YoY (%)(%) | 8.5% | 15.0% | 1.1% | 8.0% | 0.3% | 1.2% | -0.6% | 2.9% | 13.2% | -6.5% | -9.5% | 4.9% | |
Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — International Reported Sales Growth YoY (%)(%) | 8.1% | 17.9% | 8.3% | 13.7% | 2.8% | 3.4% | -4.3% | 0.1% | 12.7% | -8.7% | -10.3% | 6.0% | |
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — Worldwide Net Sales ($M)($M)4 | 566 | 496 | 517 | 539 | 525 | 498 | 406 | 341 | 329 | 327 | 310 | 320 | |
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — Worldwide Constant Currency Sales Growth YoY (%)(%) | 7.4% | -1.8% | 24.0% | 55.8% | 58.9% | 50.7% | 33.3% | 7.8% | 5.9% | 8.0% | 11.4% | 6.6% | |
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — Worldwide Reported Sales Growth YoY (%)(%) | 8.0% | -0.7% | 27.5% | 58.1% | 59.6% | 52.3% | 31.0% | 6.8% | 5.5% | 5.3% | 9.1% | 6.7% | |
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — U.S. Net Sales ($M)($M)1 | 320 | 250 | 280 | 294 | 283 | 268 | 203 | 137 | 121 | 127 | 121 | 122 | |
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%) | 13.0% | -6.7% | 37.9% | 115.9% | 136.9% | 111.0% | 67.0% | 12.0% | 1.5% | 2.3% | 2.9% | 7.6% | |
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — International Net Sales ($M)($M)2 | 246 | 246 | 237 | 245 | 242 | 230 | 203 | 204 | 208 | 200 | 189 | 198 | |
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — International Constant Currency Sales Growth YoY (%)(%) | 0.8% | 4.0% | 10.5% | 15.8% | 12.4% | 11.7% | 11.1% | 5.3% | 8.6% | 11.8% | 17.5% | 6.1% | |
Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — International Reported Sales Growth YoY (%)(%) | 2.1% | 6.3% | 17.0% | 19.6% | 14.3% | 15.0% | 7.9% | 3.6% | 8.1% | 7.3% | 13.4% | 6.2% | |
Orthopaedics Segment — Worldwide Net Sales ($M)($M)4 | 2,856 | 2,964 | 2,813 | 3,195 | 2,702 | 2,717 | 2,810 | 2,258 | 2,170 | 2,207 | 2,146 | 2,388 | |
Orthopaedics — Worldwide Constant Currency Growth YoY (%)(%) | 5.9% | 8.7% | -1.8% | ||||||||||
Orthopaedics — Worldwide Reported Growth YoY (%)(%) | 5.7% | 9.1% | 0.1% | ||||||||||
Orthopaedics — U.S. Net Sales ($M)($M) | 2,046 | 2,105 | 1,982 | 2,319 | 1,921 | 1,928 | 2,023 | 2,193 | 1,842 | 1,891 | 1,842 | 1,993 | |
Orthopaedics — International Net Sales ($M)($M) | 810 | 859 | 831 | 876 | 781 | 789 | 787 | 843 | 746 | 758 | 727 | 757 | |
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — Worldwide Net Sales ($M)($M)5 | 754 | 717 | 646 | 853 | 651 | 649 | 617 | ||||||
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — Worldwide Constant Currency Sales Growth YoY (%)(%) | 16.0% | 10.0% | 3.2% | ||||||||||
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — Worldwide Reported Sales Growth YoY (%)(%) | 15.8% | 10.3% | 4.8% | ||||||||||
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — U.S. Net Sales ($M)($M)1 | 576 | 530 | 467 | 657 | 487 | 483 | 459 | 520 | 429 | 463 | 434 | 495 | |
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%) | 18.1% | 9.5% | 2.0% | ||||||||||
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — International Net Sales ($M)($M)2 | 178 | 187 | 179 | 196 | 164 | 166 | 158 | 184 | 148 | 146 | 153 | 171 | |
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — International Constant Currency Sales Growth YoY (%)(%) | 9.5% | 11.8% | 6.5% | ||||||||||
Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — International Reported Sales Growth YoY (%)(%) | 9.0% | 12.8% | 12.9% | ||||||||||
Other Orthopaedics (Legacy Pre-2026 Basis, through FY2025Q4) — Worldwide Net Sales ($M)($M)3 | 267 | 203 | 183 | 162 | 222 | 127 | 136 | 133 | 166 | ||||
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — Worldwide Net Sales ($M)($M)4 | 635 | 693 | 670 | 749 | 628 | 640 | 639 | 687 | 570 | 602 | 588 | 630 | |
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — Worldwide Constant Currency Sales Growth YoY (%)(%) | 1.2% | 8.0% | 2.8% | 7.9% | 9.6% | 5.6% | 9.8% | 9.5% | 10.7% | 8.0% | 4.5% | 13.9% | |
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — Worldwide Reported Sales Growth YoY (%)(%) | 1.1% | 8.4% | 4.7% | 8.9% | 10.2% | 6.3% | 8.7% | 9.0% | 10.6% | 7.1% | 4.0% | 14.2% | |
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — U.S. Net Sales ($M)($M)1 | 458 | 488 | 472 | 548 | 452 | 460 | 464 | 509 | 417 | 433 | 429 | 469 | |
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%) | 1.3% | 6.2% | 1.4% | 7.6% | 8.4% | 6.2% | 8.3% | 8.5% | 8.4% | 6.6% | 3.1% | 12.9% | |
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — International Net Sales ($M)($M)2 | 177 | 205 | 198 | 201 | 176 | 180 | 175 | 178 | 153 | 169 | 159 | 161 | |
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — International Constant Currency Sales Growth YoY (%)(%) | 1.1% | 12.4% | 6.1% | 8.8% | 12.7% | 4.1% | 13.9% | 12.3% | 17.4% | 11.7% | 8.2% | 16.9% | |
Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — International Reported Sales Growth YoY (%)(%) | 0.5% | 14.0% | 13.5% | 12.8% | 14.9% | 6.5% | 10.0% | 10.7% | 17.1% | 8.2% | 6.3% | 18.0% | |
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — Worldwide Net Sales ($M)($M)4 | 453 | 479 | 460 | 499 | 457 | 466 | 443 | 463 | 420 | 428 | 393 | 414 | |
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — Worldwide Constant Currency Sales Growth YoY (%)(%) | -0.7% | 2.6% | 1.2% | 6.6% | 7.9% | 7.5% | 14.1% | 12.2% | 16.2% | 10.6% | 6.1% | 10.3% | |
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — Worldwide Reported Sales Growth YoY (%)(%) | -1.0% | 2.9% | 3.7% | 8.1% | 8.9% | 8.9% | 12.7% | 11.6% | 15.9% | 8.9% | 5.1% | 10.2% | |
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — U.S. Net Sales ($M)($M)1 | 277 | 296 | 276 | 306 | 279 | 283 | 269 | 291 | 256 | 261 | 251 | 271 | |
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%) | -0.6% | 4.9% | 2.3% | 5.6% | 8.7% | 8.4% | 7.6% | 7.1% | 10.9% | 4.3% | 6.8% | 12.9% | |
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — International Net Sales ($M)($M)2 | 176 | 183 | 184 | 193 | 178 | 183 | 174 | 172 | 164 | 167 | 142 | 143 | |
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — International Constant Currency Sales Growth YoY (%)(%) | -0.8% | -0.8% | -0.3% | 8.4% | 6.8% | 6.3% | 25.7% | 21.6% | 25.3% | 21.7% | 5.0% | 5.8% | |
Hips (Insignia, Trident II & Mako Robotic Hip Implants) — International Reported Sales Growth YoY (%)(%) | -1.7% | 0.0% | 6.0% | 12.3% | 9.2% | 9.6% | 21.7% | 20.2% | 24.8% | 16.9% | 2.1% | 5.5% | |
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — Worldwide Net Sales ($M)($M)4 | 1,010 | 1,072 | 1,035 | 1,086 | 960 | 957 | 945 | 996 | 849 | 832 | 830 | 860 | |
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — Worldwide Constant Currency Sales Growth YoY (%)(%) | 5.5% | 11.5% | 7.4% | 7.6% | 11.9% | 14.0% | 14.7% | 16.1% | 12.6% | 9.3% | 8.0% | 10.3% | |
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — Worldwide Reported Sales Growth YoY (%)(%) | 5.3% | 11.9% | 9.5% | 9.1% | 13.0% | 15.0% | 13.9% | 15.8% | 12.8% | 8.6% | 7.9% | 11.0% | |
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — U.S. Net Sales ($M)($M)1 | 735 | 791 | 767 | 808 | 703 | 702 | 713 | 744 | 621 | 610 | 611 | 633 | |
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%) | 4.5% | 12.5% | 7.6% | 8.5% | 13.2% | 15.1% | 16.6% | 17.4% | 12.9% | 9.1% | 10.3% | 12.1% | |
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — International Net Sales ($M)($M)2 | 275 | 281 | 268 | 278 | 257 | 255 | 232 | 252 | 228 | 222 | 219 | 227 | |
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — International Constant Currency Sales Growth YoY (%)(%) | 8.4% | 8.5% | 6.8% | 4.9% | 8.5% | 10.5% | 9.2% | 12.5% | 12.0% | 9.8% | 2.1% | 5.5% | |
Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — International Reported Sales Growth YoY (%)(%) | 7.5% | 10.3% | 15.3% | 10.8% | 12.5% | 14.9% | 6.0% | 11.5% | 12.6% | 7.4% | 1.7% | 8.3% | |
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — Worldwide Net Sales ($M)($M)4 | 4 | 3 | 2 | 8 | 6 | 5 | 166 | 186 | 304 | 307 | 300 | 318 | |
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — Worldwide Constant Currency Sales Growth YoY (%)(%) | -45.4% | -40.9% | -99.0% | -96.1% | -96.9% | -97.0% | -2.4% | 3.7% | 4.4% | 4.4% | 5.7% | 6.5% | |
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — Worldwide Reported Sales Growth YoY (%)(%) | -43.9% | -36.7% | -98.9% | -95.8% | -96.7% | -97.2% | -2.9% | 3.2% | 4.6% | 3.8% | 5.5% | 7.0% | |
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — U.S. Net Sales ($M)($M)1 | 0 | 0 | 0 | 0 | 0 | 0 | 118 | 129 | 119 | 124 | 117 | 125 | |
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — U.S. Sales Growth YoY (Reported / Constant Currency, %)(%) | 0.0% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% | -0.1% | 2.3% | 3.5% | 4.4% | 3.9% | 6.0% | |
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — International Net Sales ($M)($M)2 | 4 | 3 | 2 | 8 | 6 | 5 | 48 | 57 | 53 | 54 | 54 | 55 | |
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — International Constant Currency Sales Growth YoY (%)(%) | -45.4% | -40.9% | -96.6% | -87.5% | -89.7% | -90.2% | -7.6% | 6.9% | 6.8% | 4.3% | 11.1% | 7.7% | |
Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — International Reported Sales Growth YoY (%)(%) | -43.9% | -36.7% | -96.2% | -86.5% | -89.3% | -90.7% | -10.5% | 5.2% | 7.5% | 2.0% | 10.2% | 9.9% | |
Customer Contract Liabilities (Deferred Service, Protection Plans & Placed Equipment, $M)($M)2 | 960 | 997 | 1,035 | 1,024 | 939 | 1,061 | 1,028 | 978 | 1,008 | 921 | 866 | 860 | |
Accounts Receivable Allowance for Credit Losses ($M)($M) | 226 | 215 | 225 | 216 | 223 | 222 | 221 | 213 | 200 | 186 | 175 | 182 | |
Accrued Employee Compensation & Benefits Liability ($M)($M) | 1,363 | 1,105 | 885 | 1,595 | 1,306 | 1,075 | 919 | 1,403 | 1,250 | 887 | 778 | 1,478 | |
Inventories by Production Stage — Total ($M)($M)4 | 5,747 | 5,521 | 5,419 | 5,310 | 5,370 | 5,289 | 5,105 | 4,774 | 5,292 | 5,044 | 5,026 | 4,843 | |
Finished Goods Inventory ($M)($M) | 3,886 | 3,615 | 3,511 | 3,546 | 3,557 | 3,548 | 3,511 | 3,291 | 3,667 | 3,501 | 3,422 | 3,271 | |
Work-in-Process (WIP) Inventory ($M)($M) | 484 | 470 | 435 | 415 | 442 | 436 | 398 | 336 | 391 | 380 | 372 | 330 | |
Raw Materials & Supplies Inventory ($M)($M) | 1,377 | 1,436 | 1,473 | 1,349 | 1,371 | 1,305 | 1,196 | 1,147 | 1,234 | 1,163 | 1,232 | 1,242 | |
Acquisition Inventory Fair-Value Step-Up Amortization ($M)($M) | 0 | 0 | 0 | 13 | 61 | 65 | 34 | 29 | 9 | 0 | |||
Other Intangible Assets, Net ($M)($M)6 | 5,542 | 5,742 | 5,516 | 5,681 | 5,845 | 5,962 | 6,132 | 4,395 | 4,940 | 4,363 | 4,509 | 4,593 | |
Global Manufacturing Sites (sites)1 | |||||||||||||
Operating Lease Cost ($M)($M) | 52 | 53 | 56 | 52 | 48 | 52 | 53 | 46 | 47 | 50 | 47 | 45 | |
Acquisition & Integration-Related Costs (GAAP Footnote, $M)($M)3 | 17 | 25 | 19 | 33 | 39 | 78 | 185 | 21 | 48 | 14 | -13 | 13 | |
Share Repurchases — Shares Repurchased (Monthly & Quarterly, millions)(M)1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Share Repurchase Authorization Remaining (millions of shares)(M) | 33 | 1,033 | 1,033 | 1,033 | 1,033 | 1,033 | 1,033 | 1,033 | 1,033 | 1,033 | 1,033 | 1,033 | |
Inari Medical (Standalone Pre-Acquisition through FY2024Q3) — Total Revenue ($M)($M)4 | 153 | 146 | 143 | 132 | |||||||||
Inari Medical (Standalone through FY2024Q3) — Venous Thromboembolism (VTE: ClotTriever & FlowTriever) Revenue ($M)($M) | 145 | 138 | 137 | ||||||||||
Inari Medical (Standalone through FY2024Q3) — Emerging Therapies Revenue ($M)($M) | 8.04 | 8.15 | 6 | ||||||||||
Inari Medical (Standalone through FY2024Q3) — U.S. Revenue ($M)($M) | 142 | 136 | 134 | 124 | |||||||||
Inari Medical (Standalone through FY2024Q3) — International Revenue ($M)($M) | 11.5 | 10.0 | 9.51 | 7.70 | |||||||||
Inari Medical (Standalone Pre-Acquisition through FY2024Q3) — Gross Margin (%)(%)8 | 87.1% | 86.3% | 86.8% | 87.1% | |||||||||
Inari Medical (Standalone through FY2024Q3) — Gross Profit ($M)($M) | 134 | 126 | 124 | 115 | |||||||||
Inari Medical (Standalone through FY2024Q3) — Cost of Goods Sold ($M)($M) | 19.9 | 20.0 | 18.9 | 17.0 | |||||||||
Inari Medical (Standalone through FY2024Q3) — Research & Development Expense ($M)($M) | 29.4 | 24.9 | 26.9 | 22.9 | |||||||||
Inari Medical (Standalone through FY2024Q3) — Selling, General & Administrative Expense ($M)($M) | 108 | 114 | 103 | 101 | |||||||||
Inari Medical (Standalone through FY2024Q3) — Operating Income / (Loss) ($M)($M) | -13.6 | -22.4 | -17.2 | -9.30 | |||||||||
Inari Medical (Standalone through FY2024Q3) — Net Income / (Loss) ($M)($M) | -18.4 | -31.4 | -24.2 | -4.67 | |||||||||
Inari Medical (Standalone through FY2024Q3) — Operating Cash Flow ($M)($M) | 2.71 | 11.5 | -12.3 | 12.2 | |||||||||
Inari Medical (Standalone through FY2024Q3) — Capital Expenditures ($M)($M) | 2.89 | 3.76 | 1.25 | 0.91 | |||||||||
Inari Medical (Standalone Pre-Acquisition through FY2024Q3) — Inventories Total ($M)($M)7 | 55.2 | 49.4 | 44.7 | 42.9 | |||||||||
Inari Medical — U.S. FDA 510(k) Clearances (Ongoing Post-Acquisition, clearances)1 | 2 | 0 | 0 | 2 | 0 | 1 | 1 | 1 | 1 | 0 | 2 | 2 | |
Inari Medical — FDA MAUDE Adverse Event Reports (reports) | 23 | 24 | 29 | 36 | 22 | 18 | 23 | 20 | 14 | 15 | 17 | 15 | |
Stryker — U.S. FDA 510(k) Device Clearances (clearances)6 | 8 | 11 | 10 | 7 | 10 | 5 | 8 | 12 | 9 | 6 | 11 | 5 | |
U.S. MedTech Industry Total — FDA 510(k) Clearances (clearances) | 855 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
Stryker — U.S. FDA Premarket Approvals (PMA & Supplements, approvals) | 2 | 1 | 1 | 1 | 2 | 3 | 1 | 4 | 7 | 3 | 1 | 2 | |
U.S. MedTech Industry Total — FDA PMA Approvals (approvals) | 565 | 608 | 567 | 525 | 585 | 588 | 524 | 683 | 538 | 550 | 459 | 656 | |
Stryker — openFDA Device Recall Events (events) | 18 | 30 | 3 | 6 | 4 | 5 | 25 | 8 | 17 | 22 | 2 | 34 | |
Stryker — openFDA Enforcement Reports (reports) | 19 | 30 | 2 | 7 | 3 | 23 | 7 | 9 | 17 | 21 | 2 | 35 | |
Stryker — FDA MAUDE Adverse Event Reports Total (reports)4 | 2,755 | 1,856 | 2,037 | 2,668 | 2,505 | 2,693 | 2,501 | 2,796 | 2,858 | 2,411 | 2,390 | 2,477 | |
Stryker — Clinical Trials Started in Period (ClinicalTrials.gov, studies) | 4 | 3 | 2 | 1 | 1 | 1 | 4 | 5 | 3 | 4 | |||
Consolidated Net Sales ($M)($M)15 | 6,520 | 6,589 | 6,020 | 7,171 | 6,057 | 6,022 | 5,866 | 6,436 | 5,494 | 5,422 | 5,243 | 5,815 | |
Total Assets ($M)($M)11 | 47,247 | 47,930 | 46,291 | 47,844 | 47,057 | 46,331 | 46,006 | 42,971 | 43,833 | 39,130 | 39,402 | 39,912 | |
Operating Cash Flow ($M)($M)6 | 1,461 | 1,261 | 581 | 2,143 | 1,540 | 1,111 | 250 | 1,931 | 1,474 | 633 | 204 | 1,528 | |
25 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Core Operational & Franchise KPIs (Groups 1–3): Consolidated and segment Organic Sales Growth (%), MD&A Constant-Currency Unit Volume/Mix (%) vs. Selling Price (%) growth decomposition, Gross & Segment Margin Bridge drivers (bps), Full-Year Organic Sales & Adjusted EPS Guidance ranges, and all 9 active Q1-2026 franchises across Worldwide, U.S., and International markets plus standalone Other Orthopaedics (Mako SmartRobotics Capital), Orthopaedic Instruments, Neuro Cranial, and Enabling Technologies sub-portfolios.
- Q1 2026 Ortho Tech & Instruments Reclassification (Step 5): Effective Q1 2026, Stryker formed Ortho Tech by moving Orthopaedic Instruments and Enabling Technologies out of Instruments into Orthopaedics, and folded Neuro Cranial into Instruments. Official recast schedules (FY2023Q1–FY2026Q3) are merged seamlessly; pre-2026 historical series are preserved as labeled Legacy child rows through FY2025Q4.
- Consolidated − Standalone Evaluation (Step 3 & Step 4): Stryker Corporation files consolidated US GAAP financial statements on Form 10-K/10-Q without parent-only Schedule I financial statements, so consolidated − standalone subtraction does not apply. Instead, acquired peripheral vascular leader Inari Medical, Inc. (Nasdaq: NARI, CIK 0001531048 — acquired Feb 2025 for $4,810M) and Stryker UK Limited (Co. 03669454) are tracked directly from their self-reported filings in Groups 5–6.
- Period Splitting (Step 4): Only cumulative-to-period subtraction (FY − 9M and YTD − prior YTD on identical reporting versions) is used for Q4 2025 recast sub-portfolios, XBRL/DB Q4 segment values, and Q2–Q4 cash flow statements. Zero self-calculated ratios, margins, shares, sums, or YoY rates exist anywhere in output/kpis.json.
Không hiện vì thiếu các kỳ gần đây (12)
- Mako SmartRobotics Global Installed Base ('more than 3,000 systems worldwide') & Cumulative Procedures ('more than 2,000,000' / '2.5M+') — Disclosed as lower bounds ('more than 3,000', 'over two-thirds of knees', 'over one-third of hips', '200+ Mako systems contracted for ASCs', '460+ ASC partnerships'); excluded as bounded figures.
- Annual Patients Impacted Worldwide ('more than 150 million patients annually') — Disclosed as lower bounds ('more than 150 million' in 2024–2025, 'more than 130 million' in 2022); excluded as bounded figures.
- Earnings Call Transcript Franchise & U.S./International Organic Sales Growth % (Q2 2025, Q4 2025, Q2 2026, Q3 2026) — During the Q1 2026 earnings call (late-quarter cybersecurity incident), management did not provide organic growth figures by division/region, leaving the series missing FY2026Q1 (< 3 consecutive quarters); the table uses the complete 15–45 consecutive quarter Constant Currency Growth YoY (%) series from Form 8-K.
- Quarterly Consolidated & Orthopaedics Selling Price Impact YoY % (Form 10-Q MD&A) — In Q2 2026, consolidated pricing was flat ('Pricing was flat'), and Form 10-Q omitted the price change clause, leaving the quarterly series missing FY2026Q2; retained a continuous 7-year annual series (FY2019–FY2025) and the full quarterly series for MedSurg & Neurotechnology.
- Monthly Share Repurchase Average Price Paid per Share ($) — In months with no share repurchases (Q1–Q2 2026 and 07/2026 = 0 shares), the average purchase price is undefined, leaving only the 2 most recent months (2026-08, 2026-09 < 3 consecutive months).
- Purchased Energy Use by Fuel Type (Non-Renewable, Renewable, Natural Gas, Total TJ — FY2019–FY2022) — The 2024–2025 Comprehensive Report discontinued disclosure of the detailed TJ table by fuel, missing FY2024–FY2025.
- Manufacturing Total Recordable Incident Rate (TRIR: 0.95 in FY2022 vs. 0.68 in FY2025) — Only reports 2 endpoints (FY2022 and FY2025), missing FY2024 and therefore lacking the 2 most recent consecutive years.
- External Industry, FDA Regulatory, Clinical Trials & U.S. Federal Contracts › U.S. Hospitals Quarterly Revenue (Census QSS REV622TAXABL144QNSA, $M) — Fewer than 3 consecutive quarters / 3 consecutive months through FY2026Q3 / 2026-09 or 2 consecutive years through FY2025
- Database Context — Operating Segments & Geographic Disaggregation › MedSurg and Neurotechnology — Segment Revenue ($M) › MedSurg and Neurotechnology — Segment Depreciation & Amortization ($M) — Fewer than 3 consecutive quarters / 3 consecutive months through FY2026Q3 / 2026-09 or 2 consecutive years through FY2025
- Database Context — Operating Segments & Geographic Disaggregation › MedSurg and Neurotechnology — Segment Revenue ($M) › MedSurg and Neurotechnology — Segment Total Assets ($M) — Fewer than 3 consecutive quarters / 3 consecutive months through FY2026Q3 / 2026-09 or 2 consecutive years through FY2025
- Database Context — Operating Segments & Geographic Disaggregation › Orthopaedics — Segment Revenue ($M) › Orthopaedics — Segment Depreciation & Amortization ($M) — Fewer than 3 consecutive quarters / 3 consecutive months through FY2026Q3 / 2026-09 or 2 consecutive years through FY2025
- Database Context — Operating Segments & Geographic Disaggregation › Orthopaedics — Segment Revenue ($M) › Orthopaedics — Segment Total Assets ($M) — Fewer than 3 consecutive quarters / 3 consecutive months through FY2026Q3 / 2026-09 or 2 consecutive years through FY2025
Dữ liệu cập nhật 2026-11-02.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Core Operational Drivers — Organic Growth, Unit Volume vs. Price, Margins & Guidance
- Consolidated Organic Net Sales Growth YoY (%) (%)26 kỳ
- MedSurg & Neurotechnology — Organic Net Sales Growth YoY (%) (%)19 kỳ
- Orthopaedics — Organic Net Sales Growth YoY (%) (%)25 kỳ
- Adjusted Non-GAAP Operating Margin (%) (%)27 kỳ
- Adjusted Non-GAAP Diluted Net Earnings per Share ($) ($)15 kỳ
- Full-Year Guidance Issued in Quarter — Organic Net Sales Growth Low End (%) (%)25 kỳ
Core Franchises — MedSurg and Neurotechnology (Worldwide, U.S. & International)
- MedSurg & Neurotechnology Segment — Worldwide Net Sales ($M) ($M)18 kỳ
- Instruments (Current Q1-2026 Basis incl. Neuro Cranial) — Worldwide Net Sales ($M) ($M)16 kỳ
- Endoscopy (Surgical Visualization, Sports Medicine, Communications & Sustainability) — Worldwide Net Sales ($M) ($M)45 kỳ
- Medical (Acute Care Beds, Emergency Care LIFEPAK/LUCAS, Sage & Vocera) — Worldwide Net Sales ($M) ($M)45 kỳ
- Vascular (Neurovascular Ischemic/Hemorrhagic Stroke & Inari Peripheral Vascular) — Worldwide Net Sales ($M) ($M)24 kỳ
- Legacy Segment History (Pre-2022 Reorganization, through FY2021Q3) — MedSurg Only Worldwide Sales ($M) ($M)16 kỳ
Core Franchises — Orthopaedics, Ortho Tech & Mako SmartRobotics Capital (Worldwide, U.S. & International)
- Orthopaedics Segment — Worldwide Net Sales ($M) ($M)18 kỳ
- Ortho Tech (Mako SmartRobotics, Enabling Tech & Orthopaedic Instruments) — Worldwide Net Sales ($M) ($M)7 kỳ
- Knees (Triathlon Primary/Revision & Mako Robotic Knee Implants) — Worldwide Net Sales ($M) ($M)45 kỳ
- Hips (Insignia, Trident II & Mako Robotic Hip Implants) — Worldwide Net Sales ($M) ($M)45 kỳ
- Trauma and Extremities (Core Trauma, Upper Extremities / Shoulder & Foot/Ankle) — Worldwide Net Sales ($M) ($M)45 kỳ
- Spinal Implants (Reflects May 2025 U.S. Spinal Implants Divestiture to VB Spine) — Worldwide Net Sales ($M) ($M)45 kỳ
Commercial Contract Liabilities, Inventory Stages, Intangibles, Global Footprint & Buybacks
- Customer Contract Liabilities (Deferred Service, Protection Plans & Placed Equipment, $M) ($M)20 kỳ
- Inventories by Production Stage — Total ($M) ($M)20 kỳ
- Other Intangible Assets, Net ($M) ($M)20 kỳ
- Global Manufacturing Sites (sites)9 kỳ
- Acquisition & Integration-Related Costs (GAAP Footnote, $M) ($M)18 kỳ
- Share Repurchases — Shares Repurchased (Monthly & Quarterly, millions) (M)72 kỳ
SASB Quality & FDA Inspections Scorecard, Patents, Workforce, Governance & ESG
- SASB Quality Scorecard — U.S. FDA Inspections Conducted (inspections)8 kỳ
- Owned U.S. Patents at Year-End (patents)11 kỳ
- Global Employees at Year-End (employees)14 kỳ
- Total Scope 1 + Scope 2 (Market-Based) GHG Emissions (MT CO2e)7 kỳ
- Stryker UK Limited — Statutory Median Hourly Gender Pay Gap (%) (%)8 kỳ
Acquired Public Subsidiary — Inari Medical, Inc. (NARI, Peripheral Vascular)
- Inari Medical (Standalone Pre-Acquisition through FY2024Q3) — Total Revenue ($M) ($M)18 kỳ
- Inari Medical (Standalone Pre-Acquisition through FY2024Q3) — Gross Margin (%) (%)17 kỳ
- Inari Medical (Standalone Pre-Acquisition through FY2024Q3) — Inventories Total ($M) ($M)17 kỳ
- Inari Medical (Standalone Pre-Acquisition through FY2023) — Full-Time Employees (employees)4 kỳ
- Inari Medical — U.S. FDA 510(k) Clearances (Ongoing Post-Acquisition, clearances)105 kỳ
External Industry, FDA Regulatory, Clinical Trials & U.S. Federal Contracts
Database Context — Operating Segments & Geographic Disaggregation
Database Context — Consolidated Income Statement (US GAAP)
Database Context — Consolidated Balance Sheet (US GAAP)
Database Context — Consolidated Cash Flow Statement (US GAAP)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Stryker
- Stryker Form 10-Q — FY2026Q3 (filed 2026-10-30) ↗
- Stryker Form 10-K — FY2025 (filed 2026-02-11) ↗
- Inari Medical (NARI) 10Q — FY2024Q3 (filed 2024-10-28) ↗
- U.S. FDA openFDA Device Clearances & MAUDE — Inari Medical ↗
- U.S. FDA openFDA Device Clearances, PMA, Recalls & MAUDE — Stryker ↗
- NIH ClinicalTrials.gov Registry — Stryker ↗
- USAspending.gov Federal Prime Contract Awards — Stryker ↗
- UK Government Gender Pay Gap Service — Stryker UK Limited Co. 03669454 ↗
- Inari Medical (NARI) 10K — FY2023 (filed 2024-02-29) ↗
See a number that looks wrong?